Parallel investigations by Fan et al. identified CCL11 as a novel regulator in NAFLD pathogenesis, demonstrating that CCL11 neutralization or receptor antagonism ameliorates disease progression in knockout mouse models. Here, CCL11 is linked to metabolic dysfunction-associated steatotic liver disease.